Dr. Joensuu Discusses Resistance to Imatinib in GIST

onclivetv has 407 videos Subscribe Here

Description: Heikki Joensuu, MD from the Helsinki University Central Hospital discusses resistance to imatinib (Gleevac) high-risk patients with gastrointestinal stromal tumors (GIST) as found in the SSGXVIII/AIO study examing three Years of adjuvant imatinib as the new standard of care for high-risk GIST.
Shared By : onclivetv
Posted on : 07/05/11
Added : 6 years ago

More From onclivetv

Nothing found.